#priMe infants to stop
TB

Tuberculosis (TB) is one of the top 10 causes of death worldwide. Globally, 8.2 million people developed TB in 2023 with approximately 1.25 million dying from the disease. In children, BCG vaccination can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis. Ultimately, to interrupt transmission of the disease, highly contagious pulmonary forms of TB also need to be targeted by vaccination. The priMe project evaluates the efficacy and safety of a new vaccine candidate against TB.

About priMe

In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global emergency. Approx. 2 billion people are infected, and 10.6 million people developed TB in 2022. In the same year approx. 1.3 million died because of TB. South Africa and other Sub-Saharan countries belong to the group of “high-burden” TB countries. South Africa alone had an estimated incidence of 280.000 TB cases in 2022.

In children BCG can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis.

VPM1002 is an innovative live vaccine against TB, based on the well-known Mycobacterium bovis (M. bovis) Bacille Calmette-Guérin (BCG) strain which has been administered approximately 4 billion times worldwide.

The genetic modifications of VPM1002, namely introduction of listeriolysin while simultaneously deleting the gene for urease C in the BCG genome, are aiming for better recognition by the host immune system.

News and Press

28.05.2025

priMe thanks participants, families, and partners

28.05.2025 #priMe thanks participants, families, and partners The priMe project extends sincere thanks to the participants and families who took part in the trial, as well as the dedicated clinical sites, investigators, and collaborators who made it possible.Through your contributions, the priMe trial has officially been completed. Results will be available soon. This marks an important milestone in the effort to develop safer an…

30.11.2023

Wrapping Up priMe’s Annual Meeting: A Journey Towards Success

30.11.2023 Wrapping Up priMe’s Annual Meeting: A Journey Towards Success With a round of applause and a plethora of insights, Day 2 marks the exciting conclusion of our priMe trial meeting in Entebbe, Uganda. Highlights of Day Two: Collective Progress: Each discussion, achievement, and partnership today propelled us closer to our goal of trial success—a testament to our collective progress. Acknowledging Contributions: Reco…

MORE NEWS